Macquarie Group’s Heron Therapeutics HRTX Stock Holding History

Macquarie Group’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-6,996	Closed	-$31K	–	1929
2022 Q3	$31K	Sell	6,996 -427	-6%	-$1.67K	﹤0.01%	2076
2022 Q2	$21K	Hold	7,423	–	–	﹤0.01%	2291
2022 Q1	$42	Hold	7,423	–	–	﹤0.01%	2198
2021 Q4	$68K	Sell	7,423 -1,898	-20%	-$19.4K	﹤0.01%	2064
2021 Q3	$100K	Buy	9,321 +5,296	+132%	+$64.5K	﹤0.01%	1984
2021 Q2	$62K	Hold	4,025	–	–	﹤0.01%	2114
2021 Q1	$65K	Sell	4,025 -1,102	-21%	-$19.6K	﹤0.01%	2009
2020 Q4	$109K	Hold	5,127	–	–	﹤0.01%	1851
2020 Q3	$76K	Buy	5,127 +800	+18%	+$12.5K	﹤0.01%	1849
2020 Q2	$64K	Buy	+4,327	New	+$71.1K	﹤0.01%	1868

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Macquarie Group's HRTX Position: Q4 2022 in Review

Macquarie Group sold out of Heron Therapeutics (HRTX) in Q4 2022, closing a stake of 6,996 shares — an estimated $31K sold.

Macquarie Group first reported a position in HRTX in Q2 2020 and held it in 10 quarters. The position peaked at $109K in Q4 2020. 176 funds tracked by Wall St. Rank hold HRTX as of Q4 2022.

Macquarie Group reported no remaining Heron Therapeutics position as of Q4 2022 after selling out during the quarter.
Macquarie Group sold 6,996 Heron Therapeutics shares in Q4 2022, an estimated $31K.
Macquarie Group first reported a position in Heron Therapeutics in Q2 2020 and held it in 10 quarters.
Macquarie Group's Heron Therapeutics position peaked at $109K in Q4 2020.
176 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2022.

Based on Macquarie Group's 13F filing for Q4 2022, filed 21 Feb 2023.